Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul 21:11:1841.
doi: 10.3389/fimmu.2020.01841. eCollection 2020.

Mechanisms Underlying Potential Therapeutic Approaches for COVID-19

Abdelouaheb Benani  1 , Sanae Ben Mkaddem  2   3
Affiliations
Review

Mechanisms Underlying Potential Therapeutic Approaches for COVID-19

Abdelouaheb Benani et al. Front Immunol. .

Abstract

Coronavirus disease (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is a betacoronavirus, and is associated with cytokine storm inflammation and lung injury, leading to respiratory distress. The transmission of the virus is mediated by human contact. To control and prevent the spread of this virus, the majority of people worldwide are facing quarantine; patients are being subjected to non-specific treatments under isolation. To prevent and stop the COVID-19 pandemic, several clinical trials are in the pipeline. The current clinical trials either target the intracellular replication and spread of the virus or the cytokine storm inflammation seen in COVID-19 cases during the later stages of the disease. Since both targeting strategies are different, the window drug administration plays a crucial role in the efficacy of the treatment. Here, we review the mechanism underlying SARS-CoV-2 cell infection and potential future therapeutic approaches.

Keywords: COVID-19; SARS-CoV-2; cytokine treatment; immune therapy; monoclonal antibody; respiratory distress.

PubMed Disclaimer

References

    1. Corman VM, Lienau J, Witzenrath M. [Coronaviruses as the cause of respiratory infections]. Internist (Berl). (2019) 60:1136–45. 10.1007/s00108-019-00671-5 - DOI - PMC - PubMed
    1. Fehr AR, Channappanavar R, Perlman S. Middle east respiratory syndrome: emergence of a pathogenic human coronavirus. Annu Rev Med. (2017) 68:387–99. 10.1146/annurev-med-051215-031152 - DOI - PMC - PubMed
    1. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. . SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. (2020) 181:271–80.e8. 10.1016/j.cell.2020.02.052 - DOI - PMC - PubMed
    1. Lau JT, Yang X, Pang E, Tsui HY, Wong E, Wing YK. SARS-related perceptions in Hong Kong. Emerg Infect Dis. (2005) 11:417–24. 10.3201/eid1103.040675 - DOI - PMC - PubMed
    1. Guan Y, Zheng BJ, He YQ, Liu XL, Zhuang ZX, Cheung CL, et al. . Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science. (2003) 302:276–8. 10.1126/science.1087139 - DOI - PubMed

Publication types

MeSH terms